Evidence map›Paper›PMID 33668583›Full record

ReviewCancers2021

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.

Yongde Luo, Xiaokun Li, Jianjia Ma, James L Abbruzzese, Weiqin Lu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. OncogenicCancers · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yongde LuoThe First Affiliated Hospital & School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Xiaokun LiThe First Affiliated Hospital & School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
Jianjia MaDepartment of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
James L AbbruzzeseDivision of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Weiqin LuDepartment of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.ORCID 0000-0002-6491-8203
Stony Brook University · USWenzhou Medical University · CNDuke Medical Center · US

Funding

Targeting NADPH Oxidase for Pancreatic Cancer Prevention and TherapyR01CA240818 · NCI · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.7M
Unraveling the Role of NADPH Oxidase in Inflammation-associated Pancreatic DiseasesR01DK123079 · NIDDK · UNIVERSITY OF TEXAS EL PASO · PI LU, WEIQIN · 2020 to 2024
$1.4M
Unraveling the Role of NADPH Oxidase in Inflammation-associated Pancreatic DiseasesR56DK123079 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI LU, WEIQIN · 2019 to 2019
$336k
NCI NIH HHS 1R01CA240818-01A1NCI NIH HHS R01 CA240818NIDDK NIH HHS 1R56DK123079-01, 1R01DK123079-01NIDDK NIH HHS R01 DK123079Stony Brook University Start-up Fund, SUNY Central Award, a Pilot Project Grant from DoM.U.S. Department of Defense W81XWH-20-1-0625
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and

Indexed as

FGF21inflammationKRASobesityPDAC

Identifiers

PMID33668583
PMCPMC7918840
OpenAlexW3132003125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.